Monopar Therapeutics has disclosed a series of stock transactions involving its director, Kim R. Tsuchimoto, according to a recent SEC filing. The transactions, which occurred between November 2 and November 4, 2026, include both acquisitions and disposals of shares. This activity is significant as it demonstrates the company's management's continued engagement with its stock, which may reflect confidence in the company's future prospects.

Company Background

Monopar Therapeutics operates within the pharmaceutical preparations sector, classified under the SIC code 2834. The company is listed on the Nasdaq under the ticker MNPR. Monopar is a smaller reporting company, and its recent filings indicate ongoing activity in the stock market, which may influence investor sentiment and industry trends.

What the Filing Says

The SEC filing, with accession number 0001437749-26-035039, details multiple transactions by Tsuchimoto. On November 2, Tsuchimoto acquired 1,199 shares at a price of $30 each. The following day, Tsuchimoto sold shares in various transactions, including 1,295 shares at $70.75 and 996 shares at $71.35. The filing notes that these transactions were executed under a Rule 10b5-1 Plan, which allows for pre-scheduled trading.

Impact

These transactions may affect investor perceptions regarding Monopar Therapeutics and its leadership. As Tsuchimoto continues to buy and sell shares, it could signal confidence or concerns regarding the company's direction. Other stakeholders in the pharmaceutical preparations industry may also observe these activities as they assess market trends and management strategies.

What's Next

The filing does not say what happens next.